Heart failure arises from diverse
cardiovascular diseases, including
hypertension, ischemic disease and
atherosclerosis, valvular insufficiency,
myocarditis, and
contractile protein mutations.
MicroRNAs are dysregulated in
heart failure, but identification of the specific
microRNAs involved remains incomplete. Here, we evaluate miR-25 expression in the peripheral blood from healthy,
dilated cardiomyopathy (DCM), remote
infarct (OMI), hypertensive
heart disease (HHD), and HHD resulting in
heart failure (HHDF) using q-PCR. Interestingly, we discovered miR-25 expression in humans is initially decreased at the onset of
heart failure but is later increased in end-stage
heart failure. We also show that overexpression of miR-25 in normal mice causes cardiomyocyte
fibrosis and apoptosis. However, inhibition of miR-25 in normal mice led to activate renin-angiotensin system (RAS) and
high blood pressure, mild heart dilation. Notably, the miR-25 cluster knock-out mice was also characterized
high blood pressure and no obvious cardiac function alteration.
RNA sequencing showed the alteration of miR-25 target genes in angomir-treated mice, including the
renin secretion signal related gene. In vitro, cotransfection with the miR-25
antagomir repressed
luciferase activity from a reporter construct containing the Pde3a and Cacnalc
untranslated region. In summary, miR-25 expression during different stages of
heart disease, offers a new perspective for the role of miR-25 function in
heart failure.